News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Metaphore Pharmaceuticals, Inc. To Present At The JPMorgan 23rd Annual Healthcare Conference

10/19/2005 5:11:34 PM

FT. LEE, N.J., Jan. 4 /PRNewswire/ -- Metaphore Pharmaceuticals, Inc., an emerging pharmaceutical company developing drugs for the treatment of pain, autoimmune disorders and inflammation, today announced that President and Chief Executive Officer Alan W. Dunton, M.D. will present at the JPMorgan 23rd Annual Healthcare Conference.

The presentation is scheduled to take place on Tuesday, January 11, 2005 at 2:30 PM (PT) in the Elizabethan C&D Rooms at the Westin St. Francis in San Francisco, California.

More about the Company

Metaphore Pharmaceuticals, Inc. is a privately held, emerging pharmaceutical company which discovers, develops and will market drugs that prevent and treat pain, autoimmune disorders and inflammation. The company leverages its expertise to discover and develop small molecule compounds that mimic the activity of human enzymes. Metaphore's lead compounds mimic the function of superoxide dismutase (SOD), a beneficial enzyme that serves an important protective role in the body by removing superoxide, a toxic free radical that can damage cells and tissues. Superoxide anions are implicated in a variety of diseases associated with pain and inflammation.

Metaphore has a global, multilayered intellectual property estate covering its broad class of compounds including composition of matter and use patents. This IP estate includes 70 issued and 63 pending worldwide patents.

Product candidates in U.S. clinical testing have broad therapeutic potential across a variety of diseases. Metaphore currently focuses its clinical development efforts in pain, rheumatoid arthritis and inflammatory disorders. These markets are significant in terms of scope and size. The company maintains offices in Fort Lee, New Jersey and St. Louis, Missouri. For more information on Metaphore, please visit the Web site at:

This press release contains forward-looking statements based on information available to Metaphore as of the date hereof. In some cases, you can identify these forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other comparable terminology. Metaphore's actual results could differ materially from the results stated or implied by such forward-looking statements due to a number of risks and uncertainties. These risks and uncertainties include, but are not limited to, general economic and business conditions, changes in governmental laws and regulations relating to the development and commercialization of pharmaceutical products, and competition in our industry. In addition, we are developing several products for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Metaphore disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Metaphore Pharmaceuticals, Inc.

CONTACT: Alan W. Dunton, M.D., President and Chief Executive Officer,+1-201-947-7707,, or Sara E. K. Cooper, Director ofCorporate Communications, +1-201-947-7707,, both ofMetaphore Pharmaceuticals; or Scott M. Solomon, Vice President of SharonMerrill Associates, Inc., +1-617-542-5300,; orSean Leous, Vice President of Financial Dynamics, +1-212-850-5755,, both for Metaphore Pharmaceuticals, Inc.

Read at

comments powered by Disqus